

**ACC 2014 Appropriate Use Criteria for Initial Transthoracic Echocardiography in Outpatient Pediatric Cardiology: Members of the Writing Group, Rating Panel, Indication Reviewers, and AUC Task Force—Relationships with Industry and Other Entities (Comprehensive)**

A standard exemption to the ACC RWI policy is extended to Appropriate Use Criteria writing committees, since they do not make recommendations but rather prepare background materials and typical clinical scenarios/indications that are rated independently by a separate rating panel of experts.

Participant	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
<b>Writing Group</b>						
Robert M. Campbell	None	None	None	None	None	None
Pamela S. Douglas	<ul style="list-style-type: none"> <li>• CardioDX</li> <li>• Elsevier</li> <li>• Ikaria</li> <li>• Pappas Ventures</li> <li>• UpToDate</li> </ul>	None	<ul style="list-style-type: none"> <li>• CardioDX</li> </ul>	<ul style="list-style-type: none"> <li>• Abiomed</li> <li>• Achillion</li> <li>• Atritech</li> <li>• BMS</li> <li>• DoD/ Defense Advanced Research Agency</li> <li>• Edwards Lifesciences</li> <li>• FDA</li> <li>• Gates Foundation</li> <li>• Gilead</li> <li>• HeartFlow</li> <li>• Miracor</li> <li>• NIH</li> <li>• Novartis</li> <li>• ResMed</li> <li>• Roche</li> </ul>	<ul style="list-style-type: none"> <li>• David H. Murdock Research Institute</li> <li>• Patient Advocate Foundation</li> <li>• Translational Research in Oncology (Data Safety Monitoring Board)</li> </ul>	None
Benjamin W. Eidem	None	None	None	None	None	None
Wyman W. Lai	None	None	None	None	None	<ul style="list-style-type: none"> <li>• Plaintiff, Inpatient cardiac arrest, 2013</li> </ul>
Leo Lopez	<ul style="list-style-type: none"> <li>• American Society of Echocardiography Pediatric and CHD Council</li> <li>• Intersocietal Accreditation Commission</li> <li>• Pediatric Heart Network (NHLBI)</li> </ul>	None	None	None	None	None
Ritu Sachdeva	None	None	None	None	None	None
<b>Rating Panel</b>						
Louis I. Bezold	<ul style="list-style-type: none"> <li>• Intersocietal Accreditation Commission Echocardiography Board</li> </ul>	None	None	None	None	None
William B. Blanchard	<ul style="list-style-type: none"> <li>• State of Florida CMS</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>• Children's Medical Services Cardiac Committee</li> <li>• CMS Cardiac Subcommittee</li> <li>• State of Florida Task Force on</li> </ul>	None

Participant	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
					Appropriate Use Criteria for Pediatric Echocardiography	
Jeffrey R. Boris	None	None	None	None	None	• Defendant, Sternal surgery assessment of damages, 2013
Robert M. Campbell	None	None	None	None	None	None
Bryan Cannon	• Medtronic, Data Safety Monitoring Board	• Medtronic • St. Jude Medical	None	None	None	None
Pamela S. Douglas	• CardioDX • Elsevier • Ikaria • Pappas Ventures • UpToDate	None	• CardioDX	• Abiomed • Achillion • Atritech • BMS • DoD/ Defense Advanced Research Agency • Edwards Lifesciences • FDA • Gates Foundation • Gilead • HeartFlow • Miracor • NIH • Novartis • ResMed • Roche	• David H. Murdock Research Institute • Patient Advocate Foundation • Translational Research in Oncology (Data Safety Monitoring Board)	None
Gregory J. Ensing	None	None	None	None	None	None
Craig E. Fleishman	• Gore Medical Supplies	None	None	None	None	None
Mark A. Fogel	None	None	None	• AMAG Pharmaceuticals • Edwards Scientific • NIH* • Siemens Medical Systems • Thalasemia Society	• Kerios	None
B. Kelly Han	None	None	None	• Siemens Medical Systems	None	None
Shabnam Jain	None	None	None	None	None	None
Mark B. Lewin	None	None	None	None	• NIH	• Defendant, Congenital heart disease complication, 2012
Richard H. Lockwood	None	None	None	None	• Excellus BCBS*	None
G. Paul Matherne	None	None	None	None	None	None
David Nykanen	• W.L. Gore & Associates	None	None	None	• Congenital Heart Disease Executive Subcommittee	• Defendant, Paxil exposure in pregnancy

Participant	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
					<ul style="list-style-type: none"> <li>member, SCAI</li> <li>• St. Jude Medical</li> <li>• The Heart Center at Arnold Palmer Hospital*</li> <li>• W.L. Gore &amp; Associates</li> </ul>	causing congenital heart disease, 2012
Catherine L. Webb	None	None	None	None	None	None
Robert Wiskind	None	None	None	None	None	None
<b>Reviewers</b>						
Meryl S. Cohen	None	None	None	None	<ul style="list-style-type: none"> <li>• Janssen Pharmaceutical Co.*</li> </ul>	<ul style="list-style-type: none"> <li>• Defendant, missed fetal diagnosis of heart defect, 2012</li> </ul>
Mario J. Garcia	<ul style="list-style-type: none"> <li>• Medtronic</li> </ul>	None	<ul style="list-style-type: none"> <li>• Pfizer</li> </ul>	None	None	None
Michael Gewitz	None	None	None	None	None	None
Willem A. Helbing	None	None	None	None	None	None
Alexander J. Javois	None	None	None	None	None	None
Walter H. Johnson	None	None	None	None	<ul style="list-style-type: none"> <li>• American Heart Association</li> </ul>	None
Ann Kavanaugh-McHugh	None	None	None	None	None	None
Hyun-Sook Helen Ko	None	None	None	None	None	None
Seema Mital	None	None	None	None	None	None
Andrew J. Powell	None	None	None	None	None	None
J. Carter Ralph	None	None	None	None	None	None
Arno AW Roest	None	None	None	None	None	None
Jennifer Silva	None	None	None	None	None	None
Julia Steinberger	None	None	None	None	None	None
<b>Appropriate Use Criteria Task Force</b>						
Steven R. Bailey	<ul style="list-style-type: none"> <li>• Biotronix (DSMB)</li> <li>• Boston Scientific Corporation, Inc. (DSMB)</li> </ul>	None	<ul style="list-style-type: none"> <li>• Biostar</li> </ul>	<ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> <li>• Palmaz Scientific</li> </ul>	None	None
Alan S. Brown	<ul style="list-style-type: none"> <li>• Aegerion</li> <li>• Amarin</li> <li>• Astra Zeneca</li> <li>• Gilead</li> <li>• Merck</li> <li>• Regeneron</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>• Advocate Lutheran General Hospital</li> <li>• National Lipid Association</li> </ul>	None
John U. Doherty	None	None	None	None	<ul style="list-style-type: none"> <li>• Roche</li> <li>• Takeda</li> </ul>	None
Pamela S. Douglas	<ul style="list-style-type: none"> <li>• CardioDX</li> <li>• Elsevier</li> <li>• Ikaria</li> <li>• Pappas Ventures</li> <li>• UpToDate</li> </ul>	None	<ul style="list-style-type: none"> <li>• CardioDX</li> </ul>	<ul style="list-style-type: none"> <li>• Abiomed</li> <li>• Achillion</li> <li>• Atritech</li> <li>• BMS</li> <li>• DoD/ Defense Advanced Research Agency</li> </ul>	<ul style="list-style-type: none"> <li>• David H. Murdock Research Institute</li> <li>• Patient Advocate Foundation</li> <li>• Translational Research in Oncology (DSMB)</li> </ul>	None

Participant	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
				<ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> <li>• FDA</li> <li>• Gates Foundation</li> <li>• Gilead</li> <li>• HeartFlow</li> <li>• Miracor</li> <li>• NIH</li> <li>• Novartis</li> <li>• ResMed</li> <li>• Roche</li> </ul>		
Robert C. Hendel	<ul style="list-style-type: none"> <li>• Adenosine Therapeutics, Inc.</li> <li>• Astellas Pharma</li> <li>• Bayer</li> </ul>	None	None	None	None	<ul style="list-style-type: none"> <li>• Defendant, SPECT image interpretation, 2004</li> </ul>
Christopher M. Kramer	<ul style="list-style-type: none"> <li>• Bristol Meyers Squibb</li> <li>• Heart Metabolomics</li> <li>• MyoKardia</li> <li>• St. Jude Medical</li> <li>• Synarc</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• American Heart Association*</li> <li>• NHLBI*</li> <li>• Novartis*</li> <li>• Siemens Medical Solutions</li> </ul>	None	None
Bruce D. Lindsay	<ul style="list-style-type: none"> <li>• Biosense Webster</li> <li>• Boston Scientific</li> <li>• CardiInsight</li> <li>• Medtronic</li> </ul>	None	None	None	<ul style="list-style-type: none"> <li>• Boston Scientific*</li> <li>• Medtronic*</li> <li>• St. Jude*</li> </ul>	None
Manesh R. Patel	<ul style="list-style-type: none"> <li>• Bayer Healthcare*</li> <li>• Duke CME</li> <li>• Medscape (theheart.org)</li> <li>• Ortho McNeil Jansen*</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Astra Zeneca*</li> <li>• Genzyme</li> <li>• Johnson and Johnson*</li> <li>• NHLBI*</li> </ul>	None	None
Leslee J. Shaw	<ul style="list-style-type: none"> <li>• Agency for Healthcare Research &amp; Quality (AHRQ)</li> <li>• NIH/ NHLBI</li> <li>• Patient Centered Outcomes Research Institute (PCORI)</li> </ul>	None	None	None	None	None
Raymond Stainback	None	None	None	None	None	None
L. Samuel Wann	<ul style="list-style-type: none"> <li>• Astellas Pharma</li> <li>• Janssen Pharmaceutical</li> <li>• United Healthcare</li> </ul>	None	None	None	None	<ul style="list-style-type: none"> <li>• Defendant, Sudden death after ER visit, 2009</li> <li>• Defendant, Death due to aortic dissection, 2009</li> <li>• Defendant, ER patient died after discharge, 2009</li> </ul>
Joseph M. Allen	None	None	None	None	None	None

This table represents the relevant relationships with industry and other entities that were disclosed by participants at the time of participation. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation does not imply endorsement of this document.

\*Significant (greater than \$10,000) relationship.